Hepatitis C virus NS3 serine protease as a drug discovery target

Drugs of the Future

Volumn 28, Issue 5, 2003, Pages 465-488

  McPhee, Fiona ^a   Yeung, Kap Sun ^a   Good, Andrew C ^a   Meanwell, Nicholas A ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; APC 6336; CILUPREVIR; CRA 6336; IMIDAZOLE DERIVATIVE; LEUKOCYTE ELASTASE INHIBITOR; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TRYPTASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; WO 0174768; WO 0177113; WO 0181325; WO 0208187; WO 0208198; WO 0208244; WO 0218369; WO 0248172; WO 03006490;

BINDING AFFINITY; BINDING KINETICS; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ENZYME CONFORMATION; ENZYME STRUCTURE; GENOTYPE; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN MOTIF; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 0041972700     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.05.734774     Document Type: Review

References (196)

1. Close, D. R. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis 2001, 60(Suppl. 3): iii62-7.
2. Ohbayashi, H. Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs 2002, 11: 965-80.
3. Hauptmann, J. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs: A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol 2002, 57: 751-8.
4. Kaiser, B. Factor Xa - a promising target for drug development. Cell Mol Life Sci 2002, 59: 189-92.
5. Abdel-Rahman, H.M., Al-Karamany, G.S., El-Koussi, N.A., Youssef, A.F., Kiso, Y. HIV protease inhibitors: Peptidomimetic drugs and future perspectives. Curr Med Chem 2002, 9: 1905-22.
6. Leung-Toung, R., Li, W., Tam, T.F., Karimian, K. Thiol-dependent enzymes and their inhibitors: A review. Curr Med Chem 2002, 9: 979-1002.
7. Tong, L. Viral proteases. Chem Rev 2002, 102: 4609-26.
8. Bartenschlager, R., Ahlborn-Laake, R., Mous, J., Jacobsen, H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 1993, 67: 3835-44.
9. Lin, C., Rice C.M. The hepatitis C virus NS3 serine proteinase and NS4A cofactor: Establishment of a cell-free trans-processing assay. Proc Natl Acad Sci USA 1995, 92: 7622-6.
10. Llinàs-Brunet, M., Bailey, M., Fazal, G. et al. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: Towards smaller inhibitors. Bioorg Med Chem Lett 2000, 10: 2267-70.
11. Pessi, A. A personal account of the role of peptide research in drug discovery: The case of hepatitis C. J Pept Sci 2001, 7: 2-14.
12. Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285: 110-3.
13. Lamarre, D., Bailey, M., Bolger, G. et al. The discovery of BILN 2061 - An orally bioavailable small molecule inhibitor of the HCV serine protease and a promising antiviral for treatment of hepatitis C. Hepatology 2002, 36(4, Pt 2): Abst 464.
14. Benhamou, Y., Hinrichsen, H., Sentjens, R. et al. Tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1-5, Boston) 2002, Abst 563.
15. Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244: 359-62.
16. Lavanchy D. Hepatitis C: Public health strategies. J Hepatol 1999, 31(Suppl. 1): 146-51.
17. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 2000, 75: 18-9.
18. Saito, I., Miyamura, T., Ohbayashi, A. et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990, 87: 6547-9.
19. Tanaka, Y., Hanada, K., Mizokami, M., et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002, 99: 15584-9.
20. Robertson, B., Myers, G., Howard, C. et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: Proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 1998, 143: 2493-503.
21. Miller, R.H., Purcell, R.H. Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci USA 1990, 87: 2057-61.
22. Conry-Cantilena, C., Van Raden, M., Gibble, J. et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996, 334: 1691-6.
23. Zein, C.O., Zein, N.N. Advances in therapy for hepatitis C infection. Microbes Infect 2002, 4: 1237-46.
24. Simmonds, P. Variability of the hepatitis C virus genome. Curr Stud Hematol Blood Transfus 1998, 62: 38-63.
25. Mizokami, M., Orito, E. Molecular evolution of hepatitis viruses. Intervirology 1999, 42: 159-65.
26. Bukh, J., Miller, R.H., Purcell, R.H. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin Liver Dis 1995, 15: 41-63.
27. Bukh, J., Purcell, R.H. Genomic structure and variability of hepatitis C virus. Therapies for Viral Hepatitis 1998, 133-8.
28. From Forns & Bush, Clinics in Liver Disease 1999, 3: 693.
29. Ballesteros, A.L., Tural, C., Arisa, E.R. et al. Safety of Peginterferon (Peg-IFN) and ribavirin (RBV) for chronic hepatitis C (HCV) in HIV-infected patients. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27-30, San Diego) 2002, Abst V-685.
30. Neumann, A.U., Lam, N.P., Dahari, H. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998, 282: 103-7.
31. Fang, J.W.S., Chow, V., Lau, J.Y.N. Virology of hepatitis C virus. Clin Liver Dis 1997, 1: 493-514.
32. Schalm, S.W., Hansen, B.E., Chemello, L. et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997, 26: 961-6.
33. McHutchison, J.G., Gordon, S.C., Schiff, E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339: 1485-92.
34. Zeuzem, S., Feinman, S.V., Rasenack, J. et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343: 1666-72.
35. Manns, M.P., McHutchison, J.G., Gordon, S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001, 358: 958-65.
36. Burak, K.W., Lee, S.S. Treatment options in patients with chronic hepatitis C. Can J Public Health 2000, 91 (Suppl. 1): S22-6, S24-8.
37. Chen, I.J., Neamati, N., MacKerell, A.D. Jr. Structure-based inhibitor design targeting HIV-1 integrase. Curr Drug Targets Infect Disord 2002, 2: 217-34.
38. Squires, K.E. An introduction to nucleoside and nucleotide analogues. Antivir Ther 2001, 6 (Suppl. 3): 1-14.
39. Kolykhalov, A.A., Mihalik, K., Feinstone, S.M., Rice, C.M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J Virol 2000, 74: 2046-51.
40. Tan, S-L., Pause, A., Shi, Y., Sonenberg, N. Hepatitis C therapeutics: Current status and emerging strategies. Nat Rev Drug Discov 2002, 1: 867-81.
41. Wang, Q.M., Du, M.X., Hockmanm, M.A., Johnson, R.B., Sun, X.-L. Hepatitis C virus encoded proteins: Targets for antiviral therapy. Drugs Fut 2000, 25: 933-44.
42. Beaulieu, P.L., Llinàs-Brunet, M. Therapies for hepatitis C infection: Targeting the non-structural proteins of HCV. Curr Med Chem 2002, 1: 163-76.
43. Hedstrom, L. Serine protease mechanism and specificity. Chem Rev 2002, 102: 4501-23.
44. Reed, K.E., Rice, C.M. Molecular characterization of hepatitis C virus. Curr Stud Hematol Blood Transfus 1998, 62: 1-37.
45. Love, R.A., Parge, H.E., Wickersham, J.A. et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsinlike fold and a structural zinc binding site. Cell 1996, 87: 331-42.
46. Kim, J.L., Morgenstern, K.A., Lin, C. et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996, 87: 343-55.
47. Love, R.A., Parge, H.E., Wickersham, J.A. et al. The conformation of hepatitis C virus NS3 proteinase with and without NS4A: A structural basis for the activation of the enzyme by its cofactor. Clin Diagn Virol 1998, 10: 151-6.
48. Kwong, A.D., Kim, J.L., Rao, G., Lipovsek, D., Raybuck, S.A. Hepatitis C virus NS3/4A protease. Antiviral Res 1998, 40: 1-18.
49. Bartenschlager, R., Lohmann, V., Wilkinson, T., Koch, J.O. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J Virol 1995, 69: 7519-28.
50. Barbato, G., Cicero, D.O., Nardi, M.C. et al. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J Mol Biol 1999, 289: 371-84.
51. Orru, S., Dal Piaz, F., Casbarra, A. et al. Conformational changes in the NS3 protease from hepatitis C virus strain BK monitored by limited proteolysis and mass spectrometry. Protein Sci 1999, 8: 1445-54.
52. Perni, R.B. NS3.4A protease as a target for interfering with hepatitis C virus replication. Drug News Perspect 2000, 13: 69-77.
53. Barbato, G., Cicero, D.O., Cordier, F. et al. Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain. EMBO J 2000, 19: 1195-206.
54. Archer, S.J., Camac, D.M., Wu, Z.J. et al. Hepatitis C virus NS3 protease requires its NS4A cofactor peptide for optimal binding of a boronic acid inhibitor as shown by NMR. Chem Biol 2002, 9: 79-92.
55. Hijikata, M., Mizushima, H., Tanji, Y. et al. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc Natl Acad Sci USA 1993, 90: 10773-7.
56. Yan, Y., Li, Y., Munshi, S. et al. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 1998, 7: 837-47.
57. Bartenschlager, R., Ahlborn-Laake, R., Mous, J., Jacobsen, H. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J Virol 1994, 68: 5045-55.
58. Kolykhalov, A.A., Agapov, E.V., Rice, C.M. Specificity of the hepatitis C virus NS3 serine protease: Effects of substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B cleavage sites on polyprotein processing. J Virol 1994, 68: 7525-33.
59. Zhang, R., Durkin, J., Windsor, W.T., McNemar, C., Ramanathan, L., Le, H.V. Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. J Virol 1997, 71: 6208-13.
60. Steinkuhler, C., Urbani, A., Tomei, L. et al. Activity of purified hepatitis C virus protease NS3 on peptide substrates. J Virol 1996, 70: 6694-700.
61. Bartenschlager, R., Ahlborn-Laake, L., Yasargil, K., Mous, J., Jacobsen, H. Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase. J Virol 1995, 69: 198-205.
62. Grakoui, A., McCourt, D.W., Wychowski, C., Feinstone, S.M., Rice, C.M. Characterization of the hepatitis C virus-encoded serine proteinase: Determination of proteinase-dependent polyprotein cleavage sites. J Virol 1993, 67: 2832-43.
63. Pizzi, E., Tramontano, A., Tomei, L. et al. Molecular model of the specificity pocket of the hepatitis C virus protease: Implications for substrate recognition. Proc Natl Acad Sci USA 1994, 91: 888-92.
64. Urbani, A., Bianchi, E., Narjes, F. et al. Substrate specificity of the hepatitis C virus serine protease NS3. J Biol Chem 1997, 272: 9204-9.
65. Landro, J.A., Raybuck, S.A., Luong, Y.P. et al. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: Elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping. Biochemistry 1997, 36: 9340-8.
66. Steinkuhler, C., Biasiol, G., Brunetti, M. et al. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 1998, 37: 8899-905.
67. Steinkuhler, C., Koch, U., Narjes, F., Matassa, V.G. Hepatitis C virus protease inhibitors: Current progress and future challenges. Curr Med Chem 2001, 8: 919-32.
68. Llinàs-Brunet, M, Bailey, M.D., Cameron, D. et al. (Boehringer Ingelheim Canada Ltd.). Hepatitis C inhibitor tri-peptides. WO 0009543.
69. Johansson, A., Hubatsch, I., Akerblom, E. et al. Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Left 2001, 11: 203-6.
70. Howe, A.Y., Chase, R., Taremi, S.S. et al. A novel recombinant single-chain hepatitis C virus NS3-NS4A protein with improved helicase activity. Protein Sci 1999, 8: 1332-41.
71. Hirowatari, Y., Hijikata, Y., Tanji, H. et al. Two proteinase activities in HCV polypeptide expressed in insect cells using baculovirus vector. Arch Virol 1993, 133: 349-56.
72. Sardana, V.V., Blue, J.T. (Merck and Co. Inc.). Cloning and purification of detergent-free hepatitis C NS3 protease. WO 9813482.
73. Taremi, S.S., Beyer, B., Maher, M. et al. Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci 1998, 7: 2143-9.
74. Dimasi, N., Pasquo, A., Martin, F. et al. Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein. Protein Eng 1998, 11: 1257-65.
75. Wittekind, M., Weinheimer, S., Zhang, Y., Goldfarb, V. (Bristol-Myers Squibb Co.). Modified forms of hepatitis C virus NS3 protease. WO 00040707.
76. Dunn, B.M., Bukhtiyarova, M. (Univ. of Florida). NS4A-NS3 protease catalytic domain of hepatitis C virus with protease activity and improved stability. WO 00001718.
77. Inoue, H., Sakashita, H., Shimizu, Y. et al. Expression of a hepatitis C virus NS3 protease-NS4A fusion protein in Escherichia coli. Biochem Biophys Res Commun 1998, 245: 478-82.
78. Hamatake, R., Wang, H.-G., Butcher, J.A. et al. Establishment of an in vitro assay to characterize hepatitis C virus NS3-4A protease trans-processing activity. Intervirology 1996, 39: 249-58.
79. Sali, D.L., Ingram, R., Wendel, M. et al. Serine protease of hepatitis C virus expressed in insect cells as the NS3/4A complex. Biochemistry 1998, 37: 3392-401.
80. Gallinari, P., Brennan, D.J., Nardi, C. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J Virol 1998, 72: 6758-69.
81. Poliakov, A., Hubatsch, I., Shuman, C.F., Stenberg, G., Danielson, U.H. Expression and purification of recombinant full-length NS3 protease-helicase from a new variant of hepatitis C virus. Protein Expr Purif 2002, 25: 363-71.
82. Gallinari, P., Paolini, C., Brennan, D., Nardi, C., Steinkuhler, C., De Francesco, R. Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A. Biochemistry 1999, 38: 5620-32.
83. Howe, A.Y.M., Chase, R., Taremi, S.S. et al. A novel recombinant single-chain hepatitis C virus NS3-NS4A protein with improved helicase activity. Protein Sci 1999, 8: 1332-41.
84. Yao, N., Reichert, P., Taremi, S.S., Prosise, W.W., Weber, P.C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 1999, 7: 1353-63.
85. Sudo, K., Inoue, H., Shimizu, Y. et al. Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography. Antiviral Res 1996, 32: 9-18.
86. Matayoshi, E.D., Wang, G.T., Krafft, G.A., Erickson, J. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 1990, 247: 954-8.
87. Taliani, M., Bianchi, E., Narjes, F. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. Anal Biochem 1996, 240: 60-7.
88. Liu, Y., Kati, W., Chen, C.-M., Tripathi, R., Molla, A., Kohlbrenner, W. Use of a fluorescence plate reader for measuring kinetic parameters with inner filter effect correction. Anal Biochem 1999, 267: 331-5.
89. Lim-Wilby, M.S.L., Anderson, S.M., Gaudette, J., Levy, O.E., Nolan, T., Bergum, P.W. Optimization of a continuous assay for obtaining sensitive kinetic data on the inhibition of the HCV NS3 protease. Peptides for the New Millennium, Proceedings of the American Peptide Symposium. Fields, G.B., Tam, J.P., Barany, G. (Eds.). Kluwer Academic Publishers: Dordrecht 2000, 470-1.
90. Zhang, R., Beyer, B.M., Durkin, J. et al. A continuous spectrophotometric assay for the hepatitis C virus serine protease. Anal Biochem 1999, 270: 268-75.
91. Zhang, R., Malcolm, B.A., Beyer, B.M., Njoroge, F.G., Durkin, J., Windsor, W.T. (Schering Corp.). Peptide substrates for hepatitis C virus NS3 protease assays. US 6251583.
92. Kakiuchi, N., Nishikawa, S., Hattori, M., Shimotohno, K. A high throughput assay of the hepatitis C virus nonstructural protein 3 serine proteinase. J Virol Methods 1999, 80: 77-84.
93. Fowler, A., Price-Jones, M., Hughes, K., Anson, J., Lingham, R., Schulman, M. Development of a high throughput scintillation proximity assay for hepatitis C virus NS3 protease that reduces the proportion of competitive inhibitors identified. J Biomol Screen 2000, 5: 153-8.
94. Steinkuhler, C., Biasiol, G., Cerretani, M. et al. A scintillation proximity active site binding assay for the hepatitis C virus serine protease. Anal Biochem 2002, 307: 99-104.
95. Berdichevsky, Y., Zemel, R., Bachmatov, L. et al. A novel high throughput screening assay for HCV NS3 serine protease inhibitors J Virol Methods 2003, 107: 245-55.
96. Bansal, A., Pasquinelli, C. (DuPont Pharm. Co.). Mammalian cell-based assay systems for examining hepatitis C virus NS3 protease activity and application to drug screening. WO 01002601.
97. Cho, Y.-G., Yang, S.-H., Sung, Y.-C. In vivo assay for hepatitis C viral serine protease activity using a secreted protein. J Virol Methods 1998, 72: 109-15.
98. Potts, K.E., Jackson, R.L., Patick, A.K. (Agouron Pharmaceuticals Inc.). A cell-based reporter assay for hepatitis C virus proteases and its use in antiviral drug screening. WO 00008469, US 6280940.
99. Pellerin, C., Lamarre, D. (Boerhinger Ingelheim (Canada) Ltd.). Surrogate cell-based system and method for assaying the activity of hepatitis C virus NS3 protease. WO 00066623.
100. Germann, U., Hoock, T., Kwong, A. (Vertex Pharmaceuticals Inc.). An inducible transcriptional reporter assay for proteinase activity using cleavage site-containing chimeric transcription factor as the substrate. WO 00012727.
101. Hirowatari, Y., Hijikata, M., Shimotohno, K. A novel method for analysis of viral proteinase activity encoded by hepatitis C virus in cultured cells. Anal Biochem 1995, 225: 113-20.
102. Menzel, R., Wang, S. (Small Molecule Therapeutics Inc.). Identifying protease modulators with α-donor fusion proteins releasing α-galactosidase in results to cleavage activity. WO 00039348.
103. Wood, K.V. (Promega Corp.). Luciferase assay method. US 5283179.
104. Hong, Z., Lai, V.C.H., Lau, J.Y.N. (Schering Corp.). Hepatitis C virus (HCV) protease-dependent chimeric bovine viral diarrhea virus and uses in screening for anti-HCV agents. US 6326137.
105. Hong, Z., Butkiewicz, N.J., Zhong, W. et al. (Schering-Plough Corp.). Chimeric hepatitis G/C viruses and method for screening for HCV NS3/NS4A proteinase and HCV NS5B RNA polymerase inhibitors. US 20010034019.
106. Filocamo, G., Pacini, L., Nardi, C. et al. Selection of functional variants of the NS3-NS4A protease of hepatitis C virus by using chimeric Sindbis viruses. J Virol 1999, 73: 561-75.
107. Jang, S.K., Hahm, B.S. (LG Chemicals Co. Ltd., Pohang Univ. Sci. Technol. Found.). A poliovirus system for assay of the hepatitis C virus protease and the screening for inhibitors of the protease. WO 9800548.
108. Neyts, J., Leyssen, P., De Clercq, E. Infections with flaviviridae. Verh K Acad Geneeskd Belg 1999, 61: 661-97.
109. Beames, B., Chavez, D., Lanford, R.E. GB virus B as a model for hepatitis C virus. ILAR J 2001, 42: 152-60.
110. Levine, B., Goldman, J.E., Jiang, H.H., Griffin, D.E., Hardwick, J.M. Bc1-2 protects mice against fatal alphavirus encephalitis. Proc Natl Acad Sci USA 1996, 93: 4810-5.
111. Krieger, N., Lohmann, V., Bartenschlager, R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001, 75: 4614-24.
112. Murray, E.M., Grobler, J.A., Markel, E.J. et al. Persistent replication of HCV replicons expressing the β-lactamase reporter gene in sub-populations of permissive Huh-7 cells. J Virol 2003, 77: 2928-35.
113. Yi, M., Bodola, F., Lemon, S.M. Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein. Virology 2003, 304: 197-210.
114. Blight, K.J., McKeating, J.A., Marcotrigiano, J., Rice, C.M. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 2003, 77: 3181-90.
115. Kukolj, G., Pause, A. (Boehringer Ingelheim (Canada) Ltd.). Self-replicating RNA molecule from hepatitis C virus having adaptive mutations, and its uses in screening assay for HCV replication inhibitors. WO 02052015.
116. Bartenschlager, R. Hepatitis C virus replicons: Potential role for drug development. Nat Rev Drug Discov 2002, 1: 911-6.
117. Bukh, J., Pietschmann, T., Lohmann, V. et al. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci USA 2002, 99: 14416-21.
118. Sung, V.M.-H., Shimodaira, S., Doughty, A.L. et al. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: The apoptotic effects of virus infection. J Virol 2003, 77: 2134-46.
119. Lanford, R.E., Bigger, C., Bassett, S., Klimpel, G. The chimpanzee model of hepatitis C virus infections. ILAR J 2001, 42: 117-26.
120. Mercer, D.F., Schiller, D.E., Elliott, J.F. et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001, 7: 927-33.
121. Ilan, E., Arazi, J., Nussbaum, O. et al. The hepatitis C virus (HCV)-trimera mouse: A model for evaluation of agents against HCV. J Infect Dis 2002, 185: 153-61.
122. Schiller, D., Mercer, D., Lakey, J. et al. Effect of interferon α-2B on HCV-infected SCID/UPA mice. 8th Int Symp HCV Relat Viruses (Sept 2-5, Paris) 2001, Abst P-141.
123. Di Marco, S., Rizzi, M., Volpari, C. et al. Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J Biol Chem 2000, 275: 7152-7.
124. LaPlante, S.R., Cameron, D.R., Aubry, N. et al. Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain. J Biol Chem 1999, 274: 18618-24.
125. Persson, E., Kjalke, M., Olsen, O.H. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci USA 2001, 98: 13583-8.
126. Quan, M.L., Wexler, R.R. The design and synthesis of noncovalent factor Xa inhibitors. Curr Top Med Chem 2001, 1: 137-49.
127. Wagner, J., Kallen, J., Ehrhardt, C., Evenou, J.P., Wagner, D. Rational design, synthesis, and X-ray structure of selective noncovalent thrombin inhibitors. J Med Chem 1998, 41: 3664-74.
128. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46: 3-26.
129. Veber, D.F., Johnson, S.R., Cheng, H.-Y., Smith, B.R., Ward, K.W., Kopple, K.D. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002, 45: 2615-23.
130. Williams, G.C., Sinko, P.J. Oral absorption of the HIV protease inhibitors: A current update. Adv Drug Deliv Rev 1999, 39: 211-38.
131. Kempf, D.J., Sham, H.L., Marsh, K.C. et al. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J Med Chem 1998, 41: 602-17.
132. Drusano, G.L., Bilello, J.A., Preston, S.L. et al. Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. J Infect Dis 2001, 183: 1126-9.
133. Llinàs-Brunet, M., Bailey, M., Bordeleau, J. et al. Discovery of novel tri-peptide inhibitors of the hepatitis C virus serine protease. 220th Natl Meet ACS (August 20-24, Washington, DC) 2000, Abst MEDI-018.
134. Bailey, M.D., Bordeleau, J., Brochu, C. et al. Novel C-terminal carboxylic acid tri-peptide inhibitors of the hepatitis C virus serine protease. 220th Natl Meet ACS (August 20-24, Washington, DC) 2000, Abst MEDI-088.
135. Llinàs-Brunet, M., Bailey, M., Deziel, R. et al. Studies on the C-terminal of the hexapeptide inhibitors of the hepaptitis C virus serine protease. Bioorg Med Chem Lett 1998, 8: 2719-24.
136. LaPlante, S.R., Aubry, N., Bonneau, P.R. et al. NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain. Bioorg Med Chem Lett 2000, 10: 2271-4.
137. Poupart, M.-A., Cameron, D.R., Chabot, C. et al. Solid phase synthesis of peptidomimetic inhibitors for the hepaptitis C virus NS3 protease. J Org Chem 2001, 66: 4743-51.
138. Tsantrizos, Y.S., Cameron, D.R., Faucher, A-M. et al. (Boehringer Ingelheim (Canada) Ltd.). Macrocyclic peptides active against the hepatitis c virus. WO 0059929.
139. Campbell, J.A., Good, A.C. (Bristol-Myers Squibb Co.). Hepatitis C inhibitors. WO 0260926.
140. Ingallinella, P., Altamura, S., Bianchi, E. et al. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry 1998, 37: 8906-14.
141. Narjes, F., Koehler, K., Koch, U. et al. A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 2002, 12: 701-4.
142. Colarusso, S., Gerlach, B., Koch, U. et al. Evolution, synthesis and SAR of tripeptide α-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease. Bioorg Med Chem Lett 2002, 11: 705-8.
143. Di Marco, S., Rizzi, M., Volpari, C. et al. Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J Biol Chem 2000, 275: 7152-7.
144. Nizi, E., Koch, U., Ponzi, S., Matassa, V.G., Gardelli, C. Capped dipeptide α-ketoacid inhibitors of the HCV virus NS3 protease. Bioorg Med Chem Lett 2002, 12: 3325-28.
145. Colarusso, S., Koch, U., Garlach, B. et al. Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: Discovery, initial SAR, and molecular modeling. J Med Chem 2003, 46: 345-8.
146. Colarusso, S., Gardelli, C., Gerlach, B. et al. (Ist. Ricerche Biol. Mol. P. Angeletti SpA). Peptides and their use as inhibitors of hepatitis C virus NS3 protease. WO 02079234.
147. Ingallinella, P., Fattori, D., Altamura, S. et al. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. Biochemistry 2002, 41: 5483-92.
148. Zhang, R., Durkin, J.P., Windsor, W.T. Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease. Bioorg Med Chem Lett 2002, 12: 1005-8.
149. Han, W., Hu, Z., Jiang, X., Wasserman, Z.R., Decicco, C.P. Glycine α-ketoamides as HCV NS3 protease inhibitors. Bioorg Med Chem Lett 2003, 13: 1111-4.
150. Priestley, E.S., De Lucca, I., Ghavimi, B., Erikson-Viitanen, S., Decicco, C.P. P1 phenethyl peptide boronic acid inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 2002, 12: 3199-202.
151. Glunz, P.W., Douty, B.D., Decicco, C.P. Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors. Bioorg Med Chem Lett 2003, 13: 785-8.
152. Zhang, Z., Schmitt, A.C., Jiang, W., Wasserman, Z., Decicco, C.P. Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 2003, 13: 1157-60.
153. Han, Q. (Bristol-Myers Squibb Co.). Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors. WO 0248157.
154. Priestley, E.S., Decicco, C.P. (DuPont Pharm. Co.). Lactam inhibitors of hepatitis C virus NS3 protease. WO 0107407.
155. Llinàs-Brunet, M., Bailey, M., Fazal, G. et al. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett 1998, 8: 1713-8.
156. Slater, M.J., Andrews, D.M., Baker, G. et al. Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease. Bioorg Med Chem Lett 2002, 12: 3359-62.
157. Macdonald, S.J.F., Dowle, M.D., Harrison, L.A. et al. The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase-GW311616A a development candidate. Bioorg Med Chem Lett 2001, 11: 895-8.
158. Andrews, D.M., Chaignot, H., Coomber, B.A. et al. Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substitutents. Org Lett 2002, 4: 4479-82.
159. Andrews, D.M., Carey, S.J., Chaignot, H. et al. Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepaptitis C virus NS3/4A protease. Org Lett 2002, 4: 4475-8.
160. Silver, P.J., Gordon, R.J., Pagani, E.D. et al. Biological activity of WIN 63759, an orally bioavailable inhibitor of human neutrophil elastase. Drug Dev Res 1995, 34: 306-16.
161. Combrink, K.D., Guelgeze, H.B., Meanwell, N.A. et al. 1,2-Benzisothiazol-3-one-1, 1-dioxide inhibitors of human mast cell tryptase. J Med Chem 1998, 41: 4854-60.
162. Meanwell, N.A. et al. Bristol-Myers Squibb. Unpublished results.
163. Yeung, K.S., Meanwell, N.A. A synthesis of 4-thiomethyl-benzisothiazolone-1, 1-dioxide using HDPT. Tetrahedron Lett 1998, 39: 5309-12.
164. Yeung, K.S., Meanwell, N.A. Bristol-Myers Squibb. Unpublished results.
165. Katz, B.A., Clark, J.M., Finer-Moore, J.S. et al. Design of potent selective zinc-mediated serine protease inhibitors. Nature 1998, 391: 608-12.
166. 2+-dependent inhibitor of HCV NS3 serine protease. Bioorg Med Chem Lett 2001, 11: 2355-9.
167. Sperandio, D., Gangloff, A.R., Litvak, J. et al. Highly potent non-peptidic inhibitors of the HCV NS3/4A serine protease. Bioorg Med Chem Lett 2002, 12: 3129-313.
168. Byers, L.D., Wolfenden, R. Binding of the by-product analog benzylsuccinic acid by carboxypeptidase A. Biochemistry 1973, 12: 2070-8.
169. DailyDrugNews.com (Daily Essentials). New, orally active NS3 protease inhibitor effective and safe in patients with chronic HCV infection. November 13, 2002.
170. Patick, A.K., Binford, S.L., Brothers, M.A. et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 1999, 43: 2444-50.
171. Condra, J.H., Schleif, W.A., Blahy, O.M. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374: 569-71.
172. Smith, K.A. To cure chronic HIV infection, a new therapeutic strategy is needed. Curr Opin Immunol 2001, 13: 617-24.
173. Khalili, M., Behm, B.M. Hepatitis C in the setting of HIV co-infection. Microbes Infect 2002, 4: 1247-51.
174. Soriano, V., Sulkowski, M., Bergin, C. et al. Care of patients with chronic hepatitis C and HIV co-infection: Recommendations from the HIV-HCV International Panel. AIDS 2002, 16: 813-28.
175. Saves, M., Raffi, F., Clevenbergh, P. et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2000, 44: 3451-5.
176. Heneghan, M.A. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1-5, Boston). The Investigational Drugs Database 2002, Alerts: 471865.
177. Hui, D.Y. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003, 42: 81-92.
178. Layden, T.J., Lam, N.P., Wiley, T.E. Hepatitis C viral dynamics. Clin Liver Dis 1999, 3: 793-810.
179. Layden, J.E., Layden, T.J. Viral kinetics of hepatitis C: New insights and remaining limitations. Hepatology 2002, 35: 967-70.
180. Zeuzem, S., Schmidt, J.M., Lee, J.H., Ruster, B., Roth, W.K. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996, 23: 366-71.
181. Buti, M., Sanchez-Avila, F., Lurie, Y. et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002, 35: 930-6.
182. Bergmann, J. et al. Clinical implications of a new tri-phasic model for hepatitis C viral kinetics during INF-alpha therapy. Hepatology 2001, 34: 345A.
183. Neumann, A.U., Lam, N.P., Dahari, H. et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000, 182: 28-35.
184. Rosenberg, S. Recent advances in the molecular biology of hepatitis C virus. J Mol Biol 2001, 313: 451-64.
185. Griffin, S.D., Beales, L.P., Clarke, D.S. et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, amantadine. FEBS Lett 2003, 535: 34-8.
186. Hijikata, M., Mizushima, H., Akagi, T et al. Two distinct proteinase activities required for the processing of a putative non-structural precursor
187. Pieroni, L., Santolini, E., Fipaldini, C. et al. In vitro study of the NS2-3 protease of hepatitis C virus. J Virol 1997, 71: 6373-80.
188. Wu, Z., Yao, N., Le, H.V., Weber, P.C. Mechanism of autoproteolysis at the NS2-NS3 junction of the hepatitis C virus polyprotein. Trends Biochem Sci 1998, 23: 92-4.
189. Egger, D., Wolk, B., Gosert, R. et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002, 76: 5974-84.
190. Shirota, Y., Luo, H., Qin, W., et al. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J Biol Chem 2002, 277: 11149-55.
191. Xu, Z., Choi, J., Yen, T.S. et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J 2001, 20: 3840-8.
192. Walewski, J.L., Keller, T.R., Stump, D.D., Branch, A.D. Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 2001, 7: 710-21.
193. DailyDrugNews.com (Daily Essentials). Small molecule HCV NS3 protease inhibitors discovered at Boehringer Ingelheim. September 12, 2002.
194. Wilmouth, R.C., Clifton, I.J., Robinson, C.V. et al. Structure of a specific acyl-enzyme complex formed between β-casomorphin-7 and porcine pancreatic elastase. Nat Struct Biol 1997, 4: 456-62.
195. Note added in proof. The structure of a macrocyclic inhibitor bound to the HCV NS3-NS4A complex as determined by x-ray crystallography has been reported by Boehringer Ingelheim. Tsantrizos, Y.S., Bolger, G., Bonneau, P. et al. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis c virus infection. Angew Chem Int Ed 2003, 42: 1356-60.
196. Note added in proof. Acyl sulfonamides of NS4A/B N-terminal cleavage product have also been reported to be potent HCV NS3 inhibitors. Johansson, A., Poliakov, A., Akerblom, E. Bioorg Med Chem 2003, 11: 2551-68.